TABLE 2.
Fatality proportion of transplant rejection associated with different ICI regimens and different organs of SOT
| Overall ICIs | Organ of transplant rejection No | No of death | Percentage | |
|---|---|---|---|---|
| Nivolumab (n = 96) | Kidney | 54 | 20 | 37.74% |
| Liver | 20 | 16 | 80.00%** | |
| Heart | 5 | 1 | 20.00% | |
| Lung | 1 | 1 | 100.00% | |
| NA | 16 | 2 | 12.50% | |
| Total | 96 | 40 | 41.67%* | |
| Pembrolizumab (n = 41) | Kidney | 24 | 5 | 21.74% |
| Liver | 7 | 4 | 57.14%** | |
| Heart | 1 | 0 | 0.00% | |
| NA | 9 | 0 | 0.00% | |
| Total | 41 | 9 | 21.95%* | |
| Cemiplimab (n = 7) | Kidney | 5 | 2 | 40% |
| NA | 2 | 0 | 0.00% | |
| Total | 7 | 2 | 28.57% | |
| Avelumab (n = 1) | Kidney | 1 | 0 | 0.00% |
| Kidney | 5 | 2 | 40.00% | |
| Ipilimumab (n = 6) | Liver | 1 | 0 | 0.00% |
| Total | 6 | 2 | 33.33% | |
| Nivolumab + Ipilimumab (n = 8) | kidney | 8 | 0 | 0.00% |
| Pembrolizumab + Ipilimumab (n = 7) | Kidney | 5 | 1 | 20% |
| NA | 2 | 0 | 0.00% | |
| Total | 7 | 1 | 14.29% | |
| Pembrolizumab + Nivolumab (n = 2) | Kidney | 2 | 0 | 0.00% |
| Total | 168 | 54 | 32.14% | |
*
p < 0.05, the total percentage of death of Nivolumab is higher than that of Pembrolizumab.
**
p < 0.05, the percentage of death of liver transplant rejection is higher than that of kidney transplant rejection.